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Background: The INT6 gene was first discovered as a site of integration in mouse mammary tumors by the mouse
mammary tumor virus; however, INT6’s role in the development of human breast cancer remains largely unknown.
By gene silencing, we have previously shown that repressing INT6 promotes transforming activity in untransformed
human mammary epithelial cells. In the present study, guided by microarray data of human tumors, we have
discovered a role of Int6 in stromal fibroblasts.
Results: We searched microarray databases of human tumors to assess Int6’s role in breast cancer. While INT6
expression levels, as expected, were lower in breast tumors than in adjacent normal breast tissue samples, INT6
expression levels were also substantially lower in tumor stroma. By immunohistochemistry, we determined that the
low levels of INT6 mRNA observed in the microarray databases most likely occurs in stromal fibroblasts, because far
fewer fibroblasts in the tumor tissue showed detectable levels of the Int6 protein. To directly investigate the effects
of Int6 repression on fibroblasts, we silenced INT6 expression in immortalized human mammary fibroblasts (HMFs).
When these INT6-repressed HMFs were co-cultured with breast cancer cells, the abilities of the latter to form
colonies in soft agar and to invade were enhanced. We analyzed INT6-repressed HMFs and found an increase in the
levels of a key carcinoma-associated fibroblast (CAF) marker, smooth muscle actin. Furthermore, like CAFs, these
INT6-repressed HMFs secreted more stromal cell–derived factor 1 (SDF-1), and the addition of an SDF-1 antagonist
attenuated the INT6-repressed HMFs’ ability to enhance soft agar colony formation when co-cultured with cancer cells.
These INT6-repressed HMFs also expressed high levels of mesenchymal markers such as vimentin and N-cadherin.
Intriguingly, when mesenchymal stem cells (MSCs) were induced to form CAFs, Int6 levels were reduced.
Conclusion: These data suggest that besides enhancing transforming activity in epithelial cells, INT6 repression can also
induce fibroblasts, and possibly MSCs as well, via mesenchymal-mesenchymal transitions to promote the formation of
CAFs, leading to a proinvasive microenvironment for tumorigenesis.
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The mammalian INT6 gene was first discovered in a gen-
etic screen using the mouse mammary tumor virus
(MMTV) to isolate the INT genes that mediate breast
tumorigenesis [1]. MMTV insertions into the INT6 gene
apparently cause the expression of C-terminally truncated
Int6 proteins (Int6ΔC), which when ectopically overex-
pressed induce cell transformation and tumor formation in
mouse models [2,3]. We and others [4-6] have identified an
INT6 ortholog in the fission yeast Schizosaccharomyces
pombe. While full-length human Int6 rescues the S. pombe
Int6-null phenotype, Int6ΔC does not [7]. Therefore it is
highly probable that Int6ΔC acts in a dominant-negative
fashion to promote tumor formation in mouse mammary
glands.
In human breast cancer, we and others have examined
several breast cancer cell lines but found no evidence of
Int6ΔC expression [3,8]. However, several earlier studies
have shown lower levels of INT6 expression in breast can-
cer than normal tissues supporting the possibility that Int6
acts as a tumor suppressor [9-11]. Int6 is also known as
eIF3e, a component of the eukaryote translation initiation
factor [12]; in addition, Int6 has been shown to control
nonsense-mediated mRNA decay [13]. These data suggest
that Int6 can affect efficient translation. Using S. pombe,
we revealed a new activity of Int6 — regulation of the 26S
proteasome [7], abnormality in which increases levels of
cyclin and securin, leading to abnormal mitosis and
chromosome instability. Furthermore, using mass spec-
trometry to identify all Int6-interacting proteins, we found
that Int6 is in a supercomplex—which we named the
translasome—that contains all the components needed for
translation as well as proteasome subunits [14]. This dis-
covery led to the hypothesis that Int6 can fine-tune levels
of key regulatory proteins by coordinating protein synthe-
sis and protein degradation within the translasome. As
such, Int6 reduction may induce tumor formation in
breast epithelial cells by causing a net increase in the levels
of proteins that promote tumorigenesis. In support of this
hypothesis, we and others have recently shown that
repressing INT6 expression in normal mammary epithelial
cells induces a transforming phenotype, which correlates
with the stabilization of a potent oncoprotein, Src3/AIB1,
and altered translation of the ubiquitin genes as well as of
genes controlling the epithelial-mesenchymal transition
(EMT) [8,15].
While solid tumors are mostly derived from epithelial
cells, increasing evidence suggests that the tumor micro-
environment can play important roles in influencing
tumor progression. Within the tumor microenvironment,
as much as half the mass of the tumor microenvironment
is made of stromal cells [16]. A key component of the
stroma is the fibroblast. Fibroblasts isolated from solid tu-
mors (called carcinoma-associated fibroblasts, CAFs),when co-transplanted with carcinoma cells, can strongly
promote in vivo tumor growth as well as angiogenesis and
metastasis [17-19]. Eliminating CAFs has been reported to
suppress spontaneous metastasis and to enhance the anti-
metastatic effects of chemotherapy in mouse breast cancer
models [20].
CAFs from invasive human breast carcinomas appear
to control tumor cells by secreting a number of stromal
cell-derived factors, the chief of which is stromal cell–
derived factor 1 (SDF-1), also called CXCL12 [18]. SDF-
1 signals via its cognate receptor, CXCR4. When CXCR4
is expressed on the surface of carcinoma cells, CAFs can
directly enhance the proliferation of these cells via an
SDF-1/CXCR4 paracrine loop. The most potent CAFs
for promoting tumor progression appear to be a fraction
called myofibroblasts, which are marked by the expres-
sion of smooth muscle actin (α-SMA). High levels of
myofibroblasts in CAFs correlate with robust growth of
co-transplanted xenografted human tumors [21]; fur-
thermore, in human breast cancer patients, high α-SMA
levels in the tumor stroma correlate with poor clinical
outcomes [22,23].
In this study, guided by analyses of tumor microarray
databases, we came upon the surprising finding that,
while INT6 mRNA levels are as expected lower in breast
cancer than in normal tissue, INT6 mRNA levels are
also very low in the tumor stroma. By immunohisto-
chemistry (IHC) staining, we determined that Int6 levels
are low in the fibroblasts in tumor stroma. We went on
to show that INT6 repression can induce normal mam-
mary fibroblasts to act like CAFs, apparently by activat-
ing a mesenchymal-mesenchymal transition (MMT).
Our results suggest that the reduction of Int6 can pro-
mote breast tumor formation not only by activating
oncogenic pathways in epithelial cells but also by indu-
cing a CAF-like activity in the stromal fibroblasts.
Results
Int6 is reduced in the fibroblasts in human breast cancer
To determine whether INT6 may act as a tumor sup-
pressor for breast cancer, we searched Oncomine for
gene expression changes by focusing on studies in which
normal and tumor tissues were compared. INT6 levels
were found to be significantly higher in normal tissues
compared with invasive breast tumors and premalignant
ductal carcinoma in situ (DCIS), according to data from
the TCGA project (Figure 1A, left) [24] and Curtis et al.
(data not shown) [25], respectively.
Most intriguingly, data from studies of gene expression
in the stroma showed even more drastic differences be-
tween INT6 expression levels in tumors and normal tis-
sues. For example, data from Finak et al. [9] showed that
INT6 expression levels were about 42 times lower in the
stroma of invasive carcinoma than in matched adjacent
Figure 1 (See legend on next page.)
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Figure 1 Reduction of Int6 in the fibroblasts in human breast tumors. (A) Left: gene expression data from the breast cancer TCGA project
were directly exported from Oncomine, in which mRNA levels of INT6 in normal breast tissue and invasive ductal carcinomas were compared.
INT6 mRNA levels were reported to be 50% lower in the latter. Right: stroma gene expression data in the Finak study available in Oncomine were
analyzed to show that INT6 mRNA levels were approximately 42 times higher in the tissue surrounding the normal adjacent ducts than in the
stroma in the tumor. (B) Control or INT6-repressed MCF7 cells were analyzed by Western blot (left) or IHC (right) by an anti-Int6 antibody. We
note that agreeing with our previous finding using GFP-tagging [26], Int6 is mainly cytoplasmic. (C) This is a typical IHC experiment examining
fibroblasts in the adjacent normal and tumor region from the same human tumor sample. The top pictures were captured using a 10× objective,
and one area in each was then examined by a 40× objective to reveal more details. Closed and open arrowheads mark Int6-positive vs.
Int6-negative fibroblasts. (D) The histoscore differences between the normal and tumor regions were compared by the Wilcoxon signed rank test.
While there was no difference in Int6 intensity between the normal and tumor regions (p = 0.66), a much lower percentage of Int6-positive
fibroblasts was found in the tumor. As a result, all but two samples (marked red) show lower values for tumor fibroblasts. The mean normal and
tumor histoscores are marked orange. On the right is a boxplot of the differences between normal and tumor histoscores (individual values
shown as circles, mean difference shown in orange). Mean difference ± SEM = 27.0 ± 7.2 (p < 10−3, Wilcoxon signed rank test).
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et al. [27] showed that INT6 expression levels were
lower in the stroma of invasive carcinoma and also in
DCIS than in normal tissue (data not shown).
To further examine whether Int6 is downregulated in
tumor stroma at the protein level, we established an IHC
protocol by first examining Int6 levels in parental and
INT6-silenced MCF7 cells. As shown in Figure 1B, both
Western blot and IHC showed a 50% reduction in Int6
levels in the silenced cells, suggesting that our IHC protocol
could detect Int6 with a high degree of specificity. We then
stained paraffin-embedded tumor tissues with hematoxylin
and eosin (H&E) to select 20 samples that contained
stroma at least 2 mm away from the tumor, which we and
Finak at al. defined as normal stroma [9]. In these normal
stromal regions, we readily detected fibroblasts that stained
strongly for Int6 (Figure 1C). In contrast, such Int6-positive
fibroblasts were rare in the tissue proximal (<2 mm) to
the carcinoma cells. We could also detect Int6 in plasma
cells, but the levels did not differ substantially between
normal and tumor tissues. We scored the Int6 intensity
and calculated the histoscore differences between the nor-
mal and tumor regions (Figure 1D). While there was not a
dramatic difference in Int6 intensity between the normal
and tumor regions (p = 0.66), the fraction of fibroblasts
that were Int6-positive in the normal region was much
higher (p < 0.001), leading to higher histoscores
(p = 0.0014). These data agree with the concept that Int6
reduction in stromal fibroblasts (in addition to epithelial
cells) may promote breast tumorigenesis.
Int6 reduction in normal human mammary fibroblasts
induces CAF-like properties
To investigate whether Int6 reduction in fibroblasts can
induce CAF-like activities, we repressed INT6 expression
using siRNA in h-TERT-immortalized normal human
mammary fibroblasts (HMFs) and then measured a key
CAF marker, α-SMA. As shown in Figure 2A, repressing
INT6 steadily increased α-SMA levels over a 5-day period
after gene silencing. To determine whether the increase inα-SMA levels resulted in more efficient formation of α-
SMA cables in the cells, we performed immunostaining.
As shown in Figure 2B, greater than 2.5 times more INT6-
repressed HMFs contained α-SMA cables.
CAFs are also known to influence epithelial cells by para-
crine signaling through the secretion of SDF-1. To examine
whether INT6 repression induces the expression of
CXCL12, which encodes SDF-1, in stromal fibroblast cells,
we examined INT6-repressed HMFs and found that their
mRNA levels increased over a 7-day period (Figure 2C).
Levels of secreted SDF-1 also increased in the medium of
INT6-repressed HMFs (Figure 2D). These data collectively
suggest that CAFs can be derived from fibroblasts when
Int6 levels are downregulated.
INT6-silenced HMFs enhance transforming activities in
breast cancer cells
To determine whether INT6-repressed HMFs can func-
tionally affect transforming phenotypes of breast cancer
cells, we first analyzed colony formation in soft agar with
or without co-cultured HMFs. As shown in Figure 3A,
while parental HMFs can weakly enhance colony forma-
tion by MCF7 cells in soft agar, when INT6 was repressed
in HMFs, colony formation increased 5 fold. We have ob-
tained similar results with a variant of MCF7 cells [21]
(data not shown). To further investigate this concept, we
examined two preinvasive cell lines, MCF10AT [28]
(Figure 3B) and SUM102 cells [29,30] (Figure 3C), and
found that INT6-repressed HMFs can also readily enhance
colony formation in soft agar. Next, we analyzed cell inva-
siveness using a Matrigel-coated invasion chamber and
found that INT6-repressed HMFs can more efficiently at-
tract MCF7 cells across the Matrigel, suggesting that the
invasiveness of cancer cells can be enhanced by INT6-re-
pressed HMFs (Figure 3D). To determine whether SDF-1
is a key signaling molecule secreted by INT6-repressed
HMFs to influence transforming activities in cancer cells,
we added the SDF-1 receptor antagonist AMD3100 and
found that HMF-induced colony formation in soft agar was
greatly reduced (Figure 3E), with a concurrent reduction of
Figure 2 Reduction of Int6 induces CAF-like properties in normal human mammary fibroblasts. (A) HMFs were transfected with control or
anti-INT6 siRNA. On the left, protein samples were analyzed over time by Western blots using antibodies against α-SMA and Int6. GAPDH was the
loading control. On the right, a quantification of Western blots from three separate experiments was graphed. (B) HMFs were treated with control
or anti-INT6 siRNA for 5 days and then immunostained with antibodies against α-SMA (red) and tubulins (green), and counter-stained by DAPI
(blue) to mark the nuclei. Cells containing α-SMA cables were counted (n = 100 cells). White arrow indicates a typical α-SMA cable in a cell.
Quantification of cells containing α-SMA cables is shown on the right. (C) On the left, semiquantitative RT-PCR was performed to measure CXCL12
(encoding SDF-1) mRNA levels in parental and Int6-repressed HMFs. CXCL12 mRNA levels were normalized to those of ACTB, and the normalized
CXCL12 mRNA levels in the control were set to 1. (D) The growth media of the cells from panel C were analyzed by ELISA to measure SDF-1 levels
7 days after seeding. SDF-1 levels in the control were set to 1 (n = 3 separate experiments).
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results demonstrate that INT6-repressed HMFs can
function like CAFs to enhance transforming phenotypes of
several breast cancer cell lines.
Int6 reduction may promote CAF formation via a MMT
mechanism
The mechanism(s) by which CAFs are generated are poorly
understood. However, Int6 reduction has been shown to in-
duce EMT [15], suggesting that Int6 reduction may inducemore mesenchymal traits in the cell. We thus investigated
whether INT6 repression promotes CAF-like properties by
inducing mesenchymal traits in HMFs. As shown in
Figure 4A, when INT6 expression was silenced, protein
levels of two mesenchymal markers, vimentin and
N-cadherin, showed an average increase of 1.5 and 2.5
times respectively, in two experiments.
Mesenchymal stem cells (MSCs) have been shown to pro-
duce CAF-like cells, presumably by a trans-differentiation
process called MMT, and these cells can be detected when
Figure 3 INT6-repressed HMFs enhance transformation phenotypes of breast cancer cells. (A) HMFs were transfected with either control
siRNA or anti-INT6 siRNA. A fraction of these cells was analyzed by Western blot to confirm the reduction in Int6 and α-SMA levels (data not
shown). The rest were mixed with MCF7 cells before seeding in triplicate (n = 3). The colonies in each well (a representative area from each is
shown below the graph) were counted after 15 days. We note that HMFs seeded alone do not form colonies in soft agar (column 4 and column 5).
To confirm that the emerged colonies are of cancer cells, we tagged MCF7 cells with mCherry and found that all colonies were enriched with
mCherry-positive cells (right). The HMFs were already tagged by GFP (marked by white arrow heads) [31], but we did not detect large
colonies full of GFP-positive cells. (B) MCF10AT cells were examined similarly as in panel A, except that we did not include the
HMF-alone control. (C) SUM102 cells were examined similarly as in panel B. (D) MCF7 cells were loaded in an invasion chamber and
submerged in conditioned medium from control or INT6-repressed HMFs. Invaded cancer cells from five different areas (n = 5) on each
insert membrane were counted. (E) Normal and INT6-repressed HMFs were mixed with MCF7 cells and seeded in triplicate (n = 3) into soft agar with
or without AMD3100 (500 ng/mL). Colonies were counted after 15 days. (F) INT6-repressed HMFs were co-cultured with MCF7 cells for 4 days before
AMD3100 was added (500 ng/mL). After 24 hours, the α-SMA levels in HMFs were measured by Western blot. α-SMA levels, normalized by the loading
control GAPDH from the control cells, were set as 1 (n = 4 separate experiments).
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Figure 4 INT6 repression may induce MMT. (A) HMFs were
transfected with control or anti-INT6 siRNA for 3 days, and their lysates
were analyzed by Western blots to detect the indicated proteins. Shown
here is a representative experiment in which levels of mesenchymal
markers increased when INT6 was silenced. Protein levels normalized to
GAPDH in the control cells were set to 1. (B) Human MSCs were
incubated in conditioned medium from MDA-MD-231 cells for 10 days
before they were analyzed by Western blot to detect α-SMA and Int6
as in panel A. (C) Protein levels of α-SMA and Int6 in control or
INT6-repressed MSCs were measured by Western blot over time (left).
The data from day 5 are shown as an example (right).
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as MSCs were so induced to produce CAF-like phenotype,
we found that Int6 levels were decreased in MSCs. To
directly investigate whether INT6 repression in MSCs
can also induce CAF-like activity, we repressed INT6
and found that α-SMA levels were indeed elevated in the
MSCs (Figure 4C).Discussion
In this study, we show that INT6 expression is reduced not
only in tumor cells but also in the stroma. Our IHC data il-
lustrate that this reduction is mainly due to low levels of
Int6 in fibroblasts. To directly investigate that Int6 reduc-
tion in fibroblasts is functionally relevant to tumorigenesis,
we repressed INT6 in an immortalized HMF cell line and
found that these cells can promote anchorage-independent
growth and invasion in co-cultured breast cancer cells.
These HMFs show CAF-like phenotypes—in particular,
their SDF-1 secretion is increased; SDF-1 repression can
substantially retard transformation. These results support
the model that Int6 reduction in fibroblasts can inducethem to a CAF-like state, creating a proinvasive tumor
microenviro nment.
While the presence of CAFs is widely accepted as a key
factor for promoting tumorigenesis, the origin of these
CAFs remains largely unclear. One key area of focus is the
stem cells in various stromal components (e.g., endothelial
vessels, fat) that appear to differentiate into CAFs under
the influence of cancer cells. In addition, breast cancer fre-
quently metastasizes to the bone, and it has been shown
that MSCs in the bone can be reprogrammed to form
CAFs, thus creating a microenvironment favorable for
bone metastasis [34]. In addition to these possibilities, data
from this study and others [21] support the concept that
CAFs can also be derived from fibroblasts themselves. We
further speculate that Int6 reduction may be one of the
common steps leading to the formation of CAFs, because
when MSCs were induced by co-cultured cancer cells to
form CAFs, Int6 levels were reduced, and a direct reduc-
tion of Int6 in MSCs can induce a CAF-like phenotype.
While our data are consistent with the model that Int6
reduction can induce MMT, the molecular mechanism for
how this occurs is complex and not resolved in this study.
Int6 is also known as eIF3e, a component of the transla-
tion initiation factor 3. We and others have shown that
Int6 is not essential for translation; rather, it can selectively
control the translation of a subset of genes [8,35]. In
addition, we and others have found that Int6 can control
the stability of key regulatory proteins by interacting with
26S proteasomes. Collectively, these data suggest that Int6
can control levels of key regulatory proteins via a com-
bined and coordinated alteration of translation and prote-
olysis to globally reprogram cellular activity in an efficient
manner. Targeting translation or inhibiting proteasomes
have already emerged as powerful clinical approaches to
treat cancers [36,37].
Conclusions
We have uncovered a previously unknown tumor suppres-
sor activity for Int6, namely, that its loss can stimulate the
formation of stromal fibroblasts to a CAF-like state to en-
hance transforming activities in breast epithelial cells. Our
data support a model in which CAFs can be generated not
only from MSCs but also from fibroblasts themselves
when Int6 activity is attenuated. It is possible that
Int6 inactivation promotes a mesenchymal state by alter-
ing the translation and/or stability of a subset of key
regulatory proteins.
Methods
Cells and general culture conditions
MCF7, MDA-MB-231, MCF7-ras, MCF10AT and SUM102
cells were obtained from the American Type Culture Col-
lection. HMFs (a kind gift from Charlotte Kuperwasser,
Tufts University), human MSCs, and MCF10AT cells were
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MB-231, MCF7-ras and SUM102 cells were cultured in
Dulbecco’s Modified Eagle Medium (GIBCO) supple-
mented with 5% fetal bovine serum, 100 IU/mL penicillin,
0.1 mg/mL streptomycin, and 2 mM glutamine (GIBCO).
For co-culturing HMFs with cancer cells, the former were
seeded first to allow for attachment before a 0.4-μm Milli-
cell insert (EMD Millipore) was placed on top of them.
Cancer cells were then loaded into the insert and grown on
the membrane in the insert. These thus shared the same
culture medium but were kept physically separated. SDF-1
in the culture media was detected by an enzyme-linked
immunosorbent assay (ELISA) kit from R&D Systems.
The siRNA used to knock down INT6 expression was
thoroughly tested as previously described by us and by
others [8,39].
Assays for anchorage-independent growth and invasion
The cells were seeded and grown in soft agar as de-
scribed previously [8], except that the cancer cells were
mixed with HMFs at a ratio of 1:1. Ten thousand cells
were seeded in each well of a 6-well plate. To block
SDF-1, AMD3100 (Sigma Aldrich) was added to the soft
agar culture medium. When mCherry-tagged MCF7
cells and HMFs were co-cultured, the colonies in soft
agar were examined by fluorescence microscopy on day
9. The invasion assay was performed using the BD Bio-
Coat Matrigel Invasion Chamber (BD Biosciences). After
transfection with siRNA, HMFs (1 × 104 cells/well) were
cultured for 3 days and then a Matrigel insert, loaded
with 2.5 × 104 MCF7 cells, was placed in the well. In this
setup, the medium for HMFs underneath the insert was
the source of the chemoattractants. After 2 days, the
noninvading cells on the top of the membrane were re-
moved by scrubbing with a cotton-tipped swab, while
the invaded cells on the opposite side were stained with
Diff-Quik (TECHLAB). Invaded cells from 5 different
fields of each membrane were counted under a light
microscope with a 40× objective.
Immunoblotting and protein quantification
Cell lysate preparation, immunoblotting, and protein
quantification were done as previously described [8].
The antibody against α-SMA (1:1,000) was from Dako.
The antibodies for vimentin (1:1,000) and N-cadherin
(1:1,000) were from Cell Signaling. The secondary anti-
bodies were fluorescently-conjugated IRDye 680 and
IRDye 800 from LI-COR Biosciences (1:20,000). Proteins
on the membrane were visualized and quantified by the
Odyssey infrared imaging system (LI-COR Biosciences).
Semiquantitative RT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen), and the cDNAs were generated using theSuperScript First-Strand Synthesis System (Invitrogen).
The cycle number was adjusted to allow detection within
the linear range of product amplification. The forward and
reverse primers for the SDF-1 and actin genes were (5′ to
3′): TGAGAGCTCGCTTTGAGTGA and CACCAG-
GACCTTCTGTGGAT, and GTGGGGCGCCCCAGG-
CACCA and CTCCTTAATGTCACGCACGATTTC.
Acquisition of human tissues
The samples used in this study are anonymized tissues
collected between 2000 and 2012 from several sites in the
United States and Europe by companies that specialize in
tissue acquisition. Pathologists at the hospitals where the
tissues were collected performed gross examination to set
aside enough tissue for diagnostic purposes. The patholo-
gists then cut the remaining tumor tissue in half,
flash-froze half in liquid nitrogen and fixed the other half
in formalin, to be embedded in paraffin later. The staff
pathologists at the tissue acquisition companies then
performed quality control to determine cellularity and
to confirm the histology. Because these samples are anon-
ymized, no clinical follow-up is possible. The Institutional
Review Board at Baylor College of Medicine determined
that these samples are exempt from review.
Immunohistochemistry and data analysis
We first used cell lines with different Int6 levels to
optimize the IHC protocol. These cells were lifted by
Versene (GIBCO), and fixed with 10% neutral buffered
formalin for 2 hours. The cell pellet was solidified in 4%
molten agar (Sigma) and then put in a tissue cassette be-
fore finally being embedded in paraffin. Prior to staining,
3-μm sections were cut and deparaffinized by xylenes and
a graded alcohol series. Antigen retrieval was performed
in 10 mM citrate buffer (pH = 6) in a pressurized cooker
with heating (90°C). The sample was then washed and sus-
pended in Tris-Buffered Saline and Tween 20, and 3%
H2O2 was added to block endogenous peroxidases. Two
antibodies against Int6 were tested, one of which was de-
scribed previously [8], and one of which was from Sigma.
Although both antibodies worked well, the signal-to-noise
ratio is better with the former, so it was used throughout
this study (1:200 dilution with cell pellet and 1:50 dilution
with tissues; all incubation at room temperature). A nega-
tive control was created by treating the same set of sam-
ples with non-immune antibody (Dako) matched for
species, type, isotype, and concentration. Peroxidase con-
jugation was performed using the Envision +HRP labeled
Polymer Kit from Dako, and diaminobenzidine (DAB+,
Dako) was the chromogen. The samples were also coun-
terstained with Harris Hematoxylin.
We selected 20 formalin-fixed, paraffin-embedded hu-
man breast tumors that contained “normal” stroma, defined
as regions that are at least 2 mm away from the tumor, and
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(57–255) from each region in each sample. These sam-
ples were scored by two pathologists independently.
Histoscore (possible values 0–300) was computed as the
product of the percentage of fibroblasts (possible values
0–100) that scored positive for Int6, and the intensity of
Int6 staining in fibroblasts (possible values 0–3). Differ-
ences in fibroblast Int6 histoscore and intensity between
the normal and tumor regions were assessed by the Wil-
coxon signed rank test.
Statistical analysis
For general quantification of protein intensity and cell
growth, values are shown as averages ± SEM. Unpaired
student t tests were performed to obtain p values.
Microscopy
Cells were seeded and grown on poly-L-lysine–coated cov-
erslips (BD Biosciences) and later fixed in 3.7% paraformal-
dehyde, followed by permeabilization in 0.1% Triton X-100.
Antibodies against α-SMA (1A4, Dako) and tubulin (Cell
Signaling) were used after a 1:200 dilution (2 h at room
temperature). The secondary antibody was either conju-
gated Alexa Fluor 488 or Alexa Fluor 594 from Invitrogen
(1:250, 1 h at room temperature). The samples were
mounted in Vectashield with DAPI (Vector). Images were
captured using an Olympus IX70 microscope via a 60×/1.4
oil objective and deconvolved (constrained iterative) by Sli-
debook software (Intelligent Imaging Innovations) from a
stack of 12 images collected at 0.5-μm intervals. To mark
MCF7 cells with mCherry, we constructed the pMCherry
vector by replacing the coding sequence of GFP in pEGFP-
C1 (Clontech), which carries a neomycin selectable marker,
with the coding sequence of mCherry. Subconfluent MCF7
cells were transfected and selected by neomycin. mCherry
expression in these cells was confirmed by microscopy.
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